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PharmacologyPridopidine (ACR16) belongs to a new pharmacological class of agents affecting the central nervous
system called dopaminergic stabilizers. Dopaminergic stabilizers act primarily at dopamine type 2 (D2)
receptors and display state-dependent behavioural effects. This article aims to give an overview of the
preclinical neurochemical and behavioural in vivo pharmacological properties of pridopidine. Pridopidine
was given s.c. to male Sprague–Dawley rats (locomotor, microdialysis and tissue neurochemistry) and i.p.
to Swiss male mice (tail suspension test). Pridopidine dose-dependently increased striatal tissue levels of
the dopamine metabolite 3,4-dihydroxyphenylalanin (ED50=81 μmol/kg), and prefrontal cortex dialysate
levels of dopamine and noradrenaline as measured by high performance liquid chromatography. The agent
reduced hyperlocomotion (D-amphetamine: ED50=54 μmol/kg; MK-801: ED50=40 μmol/kg), but
preserved spontaneous locomotor activity, conﬁrming state-dependent behavioural effects. In addition,
pridopidine signiﬁcantly reduced immobility time in the tail suspension test. We conclude that
pridopidine state-dependently stabilizes psychomotor activity by the dual actions of functional dopamine
D2 receptor antagonism and strengthening of cortical glutamate functions in various settings of perturbed
neurotransmission. The putative restoration of function in cortico–subcortical circuitry by pridopidine is
likely to make it useful for ameliorating several neurological and psychiatric disorders, including
Huntington's disease.+46 31 7727 701.
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NC-ND license. © 2010 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Pridopidine (ACR16; 4-[3-(methylsulfonyl)phenyl]-1-propylpi-
peridine hydrochloride; Huntexil®), originally referred to as a
modulator of dopamine neurotransmission (Sonesson et al., 2000),
belongs to a new pharmacological class of agents acting on the central
nervous system. Through their primary action at dopamine type 2
(D2) receptors, these compounds stabilize dysregulated psychomotor
functions (i.e. they reverse behavioural states originating from both
hypo- and hyper-dopaminergia), while having only subtle effects on
normal psychomotor activity (Natesan et al., 2006; Pettersson et al.,
2010; Sonesson et al., 2000). Thus, these compounds regulate both
hyper- and hypoactive functioning in areas of the brain receiving
dopamine input, leading to reduced excitatory and inhibitory stress,
resulting in improved behavioural performance. These pharmacody-
namic actions of this new class (known as dopaminergic stabilizers)do not appear to ﬁt fully into the current classiﬁcation of dopamine D2
receptor-acting compounds (Carlsson, 2000; Rung et al., 2008):
antagonists, agonists, partial agonists or inverse agonists (Strange,
2008).
Pridopidine has been shown to bind to striatal dopamine D2
receptors in vivo, in a dose range where the agent is active in models
assessing antipsychotic-like efﬁcacy, and, similar to dopamine D2
receptor antagonists, lacks intrinsic activity at dopamine D2 receptors
in vivo (Natesan et al., 2006) as well as in vitro (Dyhring et al., 2010;
Tadori et al., 2007). The functional effects of dopaminergic stabilizers
are not conﬁned to aberrations originating from the dopamine
system. Pridopidine has also been shown to reverse perturbed
behavioural patterns originating from hypoglutamatergic states
induced by the N-methyl-D-aspartate (NMDA) receptor antagonist
MK-801 (Nilsson et al., 2004; Pettersson et al., 2002; Rung et al., 2005;
Waters et al., 2002). In line with this, increased expression of the gene
encoding the activity-regulated cytoskeletal protein (Arc) has been
observed in rat cortex after acute systemic administration of
pridopidine, which is probably the result of synaptic NMDA receptor
activation (Waters et al., 2009a). Hence, at the system level,
pridopidine is hypothesized to have a dual mechanism of action
consisting of both functional modulation of dopamine transmission
and activation of cortical glutamate transmission through synaptic
NMDA receptors.
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disorders such as schizophrenia, Huntington's disease (HD) and
Parkinson's disease (PD). However, there are suggestions that
glutamate transmission, for example at the NMDA receptor subunit
NR2B, might also be involved in these disorders, for review see Loftis
and Janowsky (2003). Furthermore, pharmacological therapies
targeting the glutamate system that aim to modulate transmission
at NMDA receptors are hypothesized to be useful in schizophrenia
(Kim et al., 2009), PD (Johnson et al., 2009) and HD (Frank and
Jankovic, 2010). Based on hypotheses regarding the mode of action of
pridopidine and putative treatment opportunities, clinical trials have
been initiated and show encouraging results in patients with PD
(Tedroff et al., 2004), schizophrenia (Carlsson and Carlsson, 2006) and
HD (Tedroff et al., 2009). Pridopidine is currently in clinical
development for the treatment of HD.
The aim of this article is to give an overview of the preclinical in
vivo pharmacological studies performed during the discovery of
pridopidine. The data have previously been published, in part, in
article, patent, poster and abstract form (Pettersson et al., 2010;
Pettersson et al., 2002; Sonesson et al., 2000; Waters et al., 2002;
Waters et al., 2009a).
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats from B&K Scanbur were used for
locomotor, tissue neurochemistry and microdialysis studies. Rats
weighed 160–180 g at the time of arrival. Rats weighed 220–270 g at
the time of the locomotor and tissue neurochemistry studies and 240–
355 g at the time of microdialysis studies. They were housed ﬁve
animals per cage with lights on between 06:00 h and 18:00 h. Swiss
male mice from Depré, France (weighing 19–24 g) were used for the
tail suspension tests. All experiments were carried out in accordance
with the European Community guidelines for animal studies and with
the approval of local animal ethics committees.
2.2. Locomotor activity
Locomotor activity was recorded for 60 min in motility meters
generating a time series of x, y (horizontal activity) and z (vertical
activity) coordinates sampled at 25 Hz. This time series was
subsequently converted into locomotor variables studied at seven
frequencies from 25 Hz to 0.25 Hz (Ponten et al., 2005). For the
statistical analysis applied in the present article, only the variable
distance, derived from the highest frequency (25 Hz), was used.
Pridopidine was administered using the NeuroSearch Sweden AB
standard screening protocol for investigation of novel compounds,
consisting of subcutaneous (s.c.) injection 4 min before initiation of
locomotor recordings. D-amphetamine (1.5 mg/kg) and MK-801
(0.7 mg/kg) were injected intraperitoneally (i.p.) 6 and 86 min,
respectively, before s.c. administration of pridopidine. Our laboratory
has found that these doses and timings of D-amphetamine and MK-
801 administration produce locomotor behavioural patterns with a
high degree of inter-trial reproducibility. In the habituated-state
experiments, the animals were placed in the motility meter arena for
30 min to allow habituation before s.c. injection of pridopidine and
start of locomotor recordings.
2.3. Ex vivo tissue preparation and analysis
Animals were decapitated 64 min after drug administration and
brains dissected into striatum, cortex and limbic regions (containing
the nucleus accumbens — both the core and shell —most parts of the
olfactory tubercle and ventral pallidum). The tissue samples were
frozen immediately and stored at –80 °C before preparation, seePonten et al. (2005) for further details. Alpha-methyl-dopa (0.25 μM)
was used as internal standard in high performance liquid chroma-
tography analysis with electrochemical detection (HPLC/EC) of tissue
eluates. The separation of the monoamine transmitter substances
(noradrenaline, dopamine, 5-hydroxytryptamine [5-HT]) as well as
the amine metabolite, 3-methoxytyramine (3-MT) and acid metabo-
lites (3,4-dihydroxyphenylalanine [DOPAC], 5-hydrocyindoleacetic
acid [5-HIAA], homovanillic acid [HVA]) was performed on a reverse
phase column (Nucleosil ODS, 5 μm, 150×4.6 mm internal diameter)
with an aqueous mobile phase (1 ml/min) containing 40 mM citric
acid, 12 mMK2HPO4, 1.7 mMH3PO4, 0.35 mM sodium octylsulfate, 6%
(volume/volume) of methanol and 0.05 mM EDTA.
2.4. Microdialysis
Experiments were conducted in accordance with Waters et al.
(1993), with some modiﬁcations as described below. For experi-
ments performed in the dorsal striatum, prefrontal cortex and
nucleus accumbens, probes with an exposed length of 3, 2.5 and
2 mm of the dialysis membrane, respectively, were used. Coordi-
nates were calculated relative to bregma: prefrontal cortex
(antero-posterior, +3.2 mm from bregma; medio-lateral, 1.2 mm
from midline; and dorsal–ventral, –4.0 mm from the surface of
skull), nucleus accumbens (antero-posterior, +1.85 mm; medio-
lateral, 1.6 mm; dorsal–ventral, –7.8 mm) or dorsal striatum
(antero-posterior +1.0 mm; medio-lateral, 2.6 mm; dorsal–ven-
tral, –6.2 mm) according to Paxinos and Watson (1986). The probe
directed at the prefrontal cortex was angled 8° from the mid-
sagittal plane. Before insertion into the brain, the dialysis probes
were perfused with 0.6 ml ethanol 70% and 1 ml of Ringer solution
consecutively. The rats were housed individually in spherical cages
for 36 to 48 h before the dialysis experiments. The brains were
removed rapidly and ﬁxed in Neo-ﬁx solution (Kebo-lab, Sweden).
Determination of dialysate content of dopamine, noradrenaline, 5-
HT, DOPAC, HVA, 3-MT and 5-HIAA was performed in accordance
with the HPLC/EC system described in Ponten et al. (2005).
2.5. Tail suspension test
Four groups of 10mice eachwere used for tail suspension tests. The
ﬁrst group received saline vehicle, the second desipramine 10 mg/kg
(as method control substance), and groups three and four received
pridopidine (10 μmol/kg and 40 μmol/kg, respectively). Given that the
initial pharmacokinetic and pharmacological exploration of pridopi-
dine in mice was performed using i.p. administration, each agent was
also administered i.p. for the tail suspension test. The mice were
observed at about 27 min after dosing to conﬁrm that treatment hadno
marked effect on normal behaviour and at 30 min after dosing were
suspended by their tail in the cage. The sum of immobility periods was
recorded over a period of 6 min. Experiments were performed by
Centre de Recherches Biologiques (CERB), France.
2.6. Data analysis
Data are expressed as mean±S.E.M. percentage of vehicle-treated
group in thenormal state and thehabituated state, and asmean±S.E.M.
percentage of the D-amphetamine or MK-801 pretreated controls in
the D-amphetamine and MK-801 state experiments, respectively. The
ED50 values for DOPAC in striatum and locomotor activity were
calculated by curve ﬁtting and ﬁtted by least square minimization to
the function: End–(End–Control)/(1+(dose/ED50)Slope), where Control
is control level and End is end level. The DOPAC levels were normalized
to control (within eachexperiment), ED50 and slopewereﬁttedwith the
restrictions: ED50N0, 0.5bSlopeb3, End=350% of control. For ED50
value calculation of pridopidine-induced reduction of spontaneous or
drug-induced hyperlocomotion by D-amphetamine or MK-801,
Table 1
Ex vivo brain monoaminergic biochemistry in rats given various doses of pridopidine.
Analyte Dose of
pridopidine
(μmol/kg)
Limbic region Striatum Cortex
% of
vehicle
S.E.M. % of
vehicle
S.E.M. % of
vehicle
S.E.M.
Noradrenaline 3.7 96.2 4.0 108.2 3.8 91.0b 1.2
11 96.4 2.2 104.3 11.7 96.6 4.4
33 88.6 5.0 96.3 4.8 90.4b 2.0
100 93.8 2.8 90.8 4.5 80.8c 1.5
300 74.9c 5.1 96.7 7.0 61.8c 3.5
Dopamine 3.7 97.1 6.3 88.4 4.0 95.4 25.3
11 98.6 4.8 87.0a 3.1 154.1 39.4
33 102.0 5.2 93.5 2.1 121.4 11.3
100 88.7 3.2 83.7b 2.3 86.7 5.7
300 75.5c 1.1 70.9c 1.9 64.8b 4.3
DOPAC 3.7 97.7 4.9 95.2 2.1 89.7 17.5
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controls, respectively, and ﬁtted with the restrictions: ED50N0,
0.5bSlopeb3, End=0% of control. In addition, statistical signiﬁcance
was assessed versus appropriate control groups using the Student's t-
test. ED50 and t-tests were calculated using Excel (Microsoft).
Microdialysis data are expressed as the mean±S.E.M. percentage
of baseline. Baseline was deﬁned as the mean of the three fractions
immediately before administration of test compound. Data were
analysed using Statview (SAS Institute) by repeated measures
analysis of variance (ANOVA), and if signiﬁcant effects were found,
followed by Fischer's PLSD post hoc test.
Total immobility time in the tail suspension tests are expressed as
medians with ranges and were analysed by the non-parametric
Mann–Whitney U test.
For all tests, Pb0.05 was considered signiﬁcant.
11 102.3 4.5 101.3 5.0 117.3 8.7
33 150.9c 7.0 161.4c 3.9 136.6c 6.5
100 204.4c 10.1 242.6c 10.6 167.0c 9.8
300 255.8c 2.5 297.9c 7.8 201.6c 12.0
HVA 3.7 103.6 5.0 93.2 1.1 91.7 1.7
11 121.2b 4.7 112.5 7.5 113.2 6.4
33 167.9c 4.0 172.1c 4.5 142.9c 5.1
100 238.4c 7.5 245.3c 8.3 185.2c 7.9
300 283.2c 6.2 283.1c 8.1 222.1c 9.3
3-MT 3.7 127.7a 4.8 109.8 19.8 n.d. n.d.
11 108.4 9.3 97.5 22.0 n.d. n.d.
33 124.7 9.0 105.2 11.3 n.d. n.d.
100 109.9 4.7 95.1 9.8 n.d. n.d.
300 83.4 11.8 67.9a 6.6 n.d. n.d.2.7. Drugs
Pridopidine HCl salt (molecular weight 317.88) was synthesized
internally at NeuroSearch Sweden AB. MK-801 (dizocilpine) and
desipramine HCl was obtained from Sigma-Aldrich. D-amphetamine
was obtained from AKL (Sweden). All compounds were dissolved in
physiological saline (0.9 wt.%/volume NaCl) and injected in a volume
of 5 ml/kg, with the exception of the tail suspension tests in which
agents were injected in a volume of 10 ml/kg.5-HT 3.7 93.7 2.9 94.2 5.3 92.1 3.9
11 96.9 2.2 95.5 2.9 98.2 0.9
33 95.6 3.1 91.1 2.7 95.2 2.5
100 95.1 1.9 88.2a 3.1 93.6 2.3
300 94.4 1.9 89.3a 2.6 97.6 3.0
5-HIAA 3.7 103.0 3.4 102.2 3.3 100.3 1.5
11 102.9 2.3 103.3 4.8 97.1 3.5
33 106.7 4.1 102.7 3.2 101.5 3.1
100 110.7a 3.1 105.9 2.8 105.9 3.2
300 109.6 3.2 106.4 1.2 106.9 2.6
3-MT, 3-methoxytyramine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-
hydroxytryptamine; DOPAC, 3,4-dihydroxyphenylalanine; HVA, homovanillic acid; n.
d., not determined. aPb0.05, bPb0.01 and cPb0.001.3. Results
3.1. Ex vivo brain monoaminergic biochemistry
The main effects observed in rats were dose-dependent increases
of the dopamine metabolites DOPAC and HVA in the cortical, striatal
and limbic regions (Fig. 1; Table 1). In the striatum, DOPAC increased
to approximately 300% of the vehicle control at 300 μmol/kg s.c. The
ED50 value for increase in striatal DOPAC was calculated to be
81 μmol/kg of pridopidine (Table 2). Pridopidine induced decreases in
dopamine, noradrenaline and 5-HT in ex vivo brain tissue. The
decreases in 5-HT were less prominent and reached signiﬁcance
only in the striatum, where it decreased to 88% of vehicle group at
100 μmol/kg s.c. (Table 1).Fig. 1. Effects of pridopidine on DOPAC. Pridopidine increases 3,4-dihydroxyphenyla-
lanine (DOPAC) in the limbic forebrain, striatum and cortex of male Sprague–Dawley
rats with no pretreatment. Doses are given in μmol/kg and were administered s.c.
64 min before sacriﬁcing the animals. Data are mean±S.E.M. ***Pb0.001 vs controls.
Number of animals per dose treatment group: vehicle: n=9; 3.7 and 11 μmol/kg:
n=4; 33 and 100 μmol/kg: n=9; 300 μmol/kg: n=5.3.2. Microdialysis
The main effects of pridopidine were dose-dependent increases in
the extracellular levels of dopamine, noradrenaline, DOPAC, HVA, 3-
MT and 5-HIAA in the nucleus accumbens, dorsal striatum and
prefrontal cortex; by contrast, 5-HT increased signiﬁcantly (up to
126% of the vehicle control) only in prefrontal cortex (Fig. 2, Table 3).
At 50 μmol/kg of pridopidine, dopamine increased signiﬁcantly to
194%, 173% and 212% of the vehicle control, and noradrenaline to
157%, 300% and 209% of the vehicle control in the nucleus accumbens,
dorsal striatum and prefrontal cortex, respectively.Table 2
Summary of ED50 calculations for increase in striatal 3,4-dihydroxyphenylalanine, and
for reductions in drug-induced hyperactivity and spontaneous activity.
Neurochemical/behavioural
variable in rat
Pridopidine ED50
(μmol/kg s.c.)
95% conﬁdence
interval
Increase of DOPAC in striatum 81 71–99
Reduction of D-amphetamine
hyperactivity (15–60 min)
54 33–72
Reduction of MK-801
hyperactivity (15–60 min)
40 14–65
Reduction of spontaneous
locomotor activity (15–60 min)
n.c. (no reduction) n.c. (no reduction)
Reduction of spontaneous
locomotor activity (0–15 min)
318 248–566
DOPAC, 3,4-dihydroxyphenylalanine; n.c., not calculated.
Fig. 2. Effect of pridopidine on dialysates from: (A) striatum; (B) nucleus accumbens;
(C) cortex. Effect of pridopidine at 50 μmol/kg on extracellular levels of dopamine (DA;
n=6–14), noradrenaline (NA; n=4–8) and 5-hydroxytryptamine (5-HT; n=4–10).
Pridopidine was administered directly after collection of sample at last baseline fraction
(time=0). Data are mean±S.E.M. ***Pb0.001, **Pb0.01, *Pb0.05 vs time=0.
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3.3.1. In the normal state
In normal rats without pretreatment, pridopidine had only subtle
locomotor effects at doses up to 300 μmol/kg s.c., and signiﬁcant
effects were not noted when data were pooled for the full hour of
recording (Fig. 3). However, during the most intensive exploratory
phase (0–15 min), the highest dose tested (300 μmol/kg) decreased
locomotor activity to 58% of the vehicle-treated control group. When
the rats had become partially habituated to the motility meter arena
(15–60 min after dosing), pridopidine tended to increase locomotor
activity, and a signiﬁcant stimulant effect, 231% of vehicle, was seen at
100 μmol/kg. ED50 for reduction of spontaneous locomotor reduction
0–15 min was calculated to be 318 μmol/kg s.c. (95% conﬁdence
interval [CI]: 248–566) (Table 2). Data did not support calculation of
an ED50 for reduction of locomotor activity 15–60 min or 0–60 min.3.3.2. In the habituated state
In animals that had been habituated to themotility meter arena for
30 min before administration of pridopidine, a signiﬁcant locomotor
stimulation, to 931% of vehicle-treated control group, was induced by
the 50 μmol/kg dose during 15–60 min of locomotor recording
(Fig. 4).
3.3.3. In the D-amphetamine hyperactive state
The hyperactivity induced by D-amphetamine (1.5 mg/kg i.p.) was
dose-dependently reduced during 15–60 min of recording by prido-
pidine at 50 and 150 μmol/kg s.c. (Fig. 5A). The ED50 for the reduction
of D-amphetamine-induced hyperactivity during15–60 min was cal-
culated to be 54 μmol/kg of pridopidine (Table 2).
3.3.4. In the MK-801 hyperactive state
Pridopidine dose-dependently reversed the behavioural hyperac-
tivity induced by MK-801 (0.7 mg/kg i.p.) during 15–60 min at 50 and
150 μmol/kg s.c. (Fig. 5B). The ED50 for reduction of MK-801 induced
hyperlocomotion during 15–60 min was calculated to 40 μmol/kg of
pridopidine (Table 2).
3.4. Tail suspension test
The median immobility time in mice receiving vehicle was 42
seconds (range: 30–114 s). Corresponding data for animals receiving
pridopidine 10 or 40 μmol/kg were 10 seconds (range: 0–55 s) and
22 s (1–74 s), respectively. The variation from vehicle was signiﬁcant
for both doses of pridopidine (10 μmol/kg: Pb0.01; 40 μmol/kg:
Pb0.05) demonstrating an antidepressant-like effect. In comparison,
desipramine 10 mg/kg was associated with an immobility time of 21 s
(range: 0–38 s).
4. Discussion
4.1. Dopaminergic stabilizers as a concept
The concept of dopaminergic stabilizers has been present in the
literature for about a decade. Pridopidine (ACR16) was discovered in
1998 (Sonesson et al., 2000), and its basic pharmacology was ﬁrst
presented at scientiﬁc meetings (Pettersson et al., 2002; Waters et al.,
2002). Our paper brings these results together with further data to
provide an improved understanding of the essential pharmacology of
pridopidine in particular.
Recent in vitro investigations with pridopidine have revealed
further properties that distinguish it from other compounds that act
primarily at dopamine D2 receptors. Although pridopidine does not
have an appreciable intrinsic activity in vitro (Tadori et al., 2007) or in
vivo (Natesan et al., 2006), it has a higher in vitro afﬁnity to the
activated state of the dopamine D2 receptor (D2High) compared with
the low-afﬁnity state (Seeman et al., 2009; Waters et al., 2009b;
Pettersson et al., 2010). Preferential interaction with D2High has
previously been hypothesized to be a discrete property for com-
pounds that display intrinsic activity at dopamine D2 receptors; that
is, full and partial agonists (George et al., 1985; Seeman et al., 2003). In
addition, the functional antagonism by pridopidine at dopamine D2
receptors is fully surmountable by dopamine, and the fast recovery of
receptor responsiveness to dopamine after washout of pridopidine
suggests that it has fast-off dissociation kinetics at the dopamine D2
receptor (Dyhring et al., 2010; Waters et al., 2009a).
4.2. Antagonistic-like interaction of pridopidine with dopamine D2
receptors
Treatment with pridopidine led to signiﬁcantly increased metab-
olism of dopamine in the major dopamine projection areas of the
brain, as indicated by increased dialysate levels of the dopamine
Table 3
Results of in vivo microdialysis experiments in rats given various doses of pridopidine. Data are maximum percentage of baseline values.
Analyte Dose of
pridopidine
(μmol/kg)
Nucleus accumbens Dorsal striatum Prefrontal cortex
Max in % of baseline S.E.M n Max in % of baseline S.E.M n Max in % of baseline S.E.M n
Dopamine 5.6 n.d. n.d. 0 108.9a 3.5 8 123.0 12.6 6
16.7 127.9c 9.9 7 126.9c 2.7 7 n.d. n.d. 0
50 193.8c 14.7 7 172.8c 5.5 14 211.8c 21.0 8
DOPAC 5.6 n.d. n.d. 0 116.0c 2.4 8 123.0 12.6 6
16.7 127.8c 5.5 7 147.0c 4.8 7 n.d. n.d. 0
50 173.1c 4.9 7 218.8c 9.2 14 220.6c 13.1 8
HVA 5.6 n.d. n.d. 0 120.1c 1.7 8 121.7c 4.9 6
16.7 132.7c 5.3 7 150.9c 4.7 7 n.d. n.d. 0
50 190.3c 3.0 7 221.3c 8.3 14 208.7c 10.3 8
3-MT 5.6 n.d. n.d. 0 105.8b 2.0 8 209.5b 54.0 3
16.7 123.1c 6.8 7 121.1c 4.8 7 n.d. n.d. 0
50 168.0c 7.9 7 161.1c 3.2 14 177.9c 24.9 7
5-HT 5.6 n.d. n.d. 0 105.9 8.2 8 101.3 11.0 6
16.7 127.5a 5.9 4 115.4 7.3 4 n.d. n.d. 0
50 127.7 12.7 4 116.3 13.5 10 125.5c 7.2 8
5-HIAA 5.6 n.d. n.d. 0 102.7a 1.2 8 99.6 5.4 6
16.7 104.1a 3.1 7 103.6a 2.7 7 n.d. n.d. 0
50 113.9b 2.5 7 110.4b 4.0 14 116.1c 2.2 8
Noradrenaline 5.6 n.d. n.d. 0 113.4 10.9 8 137.1c 8.0 6
16.7 117.4 10.2 4 104.6 21.8 4 n.d. n.d. 0
50 157.3c 27.6 4 300.0c 70.6 4 209.0c 17.6 7
3-MT, 3-methoxytyramine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; DOPAC, 3,4-dihydroxyphenylalanine; HVA, homovanillic acid; .n.d., not determined.
aPb0.05, bPb0.01 and cPb0.001.
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71–99) we obtained for an increase of ex vivo tissue striatal DOPAC,
was similar to the ED50 value of 60 μmol/kg (95% CI: 36–83)
previously reported for striatal dopamine D2 receptor occupancy of
pridopidine (Natesan et al., 2006). Increased synaptic concentration
and metabolism of dopamine with pridopidine is also suggested by
the increase in extracellular concentrations of dopamine in striatal
dialysates, in combination with reduced ex vivo striatal tissue levels of
dopamine. Moreover, the level of 3-MT in striatal dialysates, which
reﬂects postsynaptic degradation of synaptically released dopamine,
also increased. Notably, dopamine D2 receptor antagonists induce
analogous neurochemical effects in the striatum (Westerink et al.,
1998; Westerink and Korf, 1976), both with respect to the pattern of
increased dopamine and 3-MT, but even more so with respect to the
quantitative and temporal increase in DOPAC and HVA.
Marked regional differences in the effects of dopamine D2 receptor
antagonists on extracellular levels of dopamine have been reported
(Moghaddam and Bunney, 1990; Westerink et al., 2001). The effects of
the atypical antipsychotic clozapine on dialysate dopamine were
smaller in the dorsal striatum than in the cortex, whereas the typical
antipsychotic haloperidol had only limited effects on dialysate dopa-
mine in the prefrontal cortex. Systemic administration of pridopidineFig. 3. Effect of pridopidine on spontaninduced a robust and rather homogenous increase in extracellular
dopamine across regions, with slightly larger increases observed in the
prefrontal cortex. The atypical antipsychotic aripiprazole, a partial
agonist at the dopamine D2 receptor, has been described as a dopamine
system stabilizer (Hirose and Kikuchi, 2005) but it produces a different
pattern of neurochemical effects in thedopamine system topridopidine.
Aripiprazole does not increase extracellular dopamine in either striatum
or medial prefrontal cortex, and it has only moderate effects on DOPAC
and HVA in these regions (Jordan et al., 2004; Semba et al., 1995).
Furthermore, striatal tissue dopamine and HVA levels remain un-
changed even at cataleptic doses of aripiprazole (Nakai et al., 2003).
Rats treated with pridopidine had increased extracellular levels of
noradrenaline in the prefrontal cortex, nucleus accumbens and dorsal
striatum. The mean increase in noradrenaline extracellular levels was
most prominent in dorsal striatum; however, baseline levels were low
and near the detection limit of the method used. In the cortex, the
basal levels of noradrenaline were higher, and changes were more
readily quantiﬁed. Notably, rats treated with pridopidine showed
decreased levels of noradrenaline in ex vivo cortical tissue homo-
genates, and increased extracellular levels in prefrontal cortex,
supporting enhanced release of noradrenaline, even at the lowest
doses tested (3.7 and 5.6 μmol/kg, respectively).eous locomotor activity. **Pb0.01.
Fig. 4. Effect of pridopidine in habituated animals. **Pb0.01.
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limited magnitude. The atypical antipsychotic olanzapine induces
regional effects on extracellular dopamine, noradrenaline and 5-HT
levels (Li et al., 1998) that are in general similar to those induced by
pridopidine in the present study. Indeed, the positive results obtained
with pridopidine in the tail suspension test may be related to these
increases in extracellular dopamine and noradenaline. Dopaminergic
and noradrenergic agents, including the dual-acting noradrenaline
and dopamine re-uptake inhibitors, have demonstrated antidepres-
sant activity in the absence of any serotonin function, by treating
symptoms associatedwith a reduced positive affect (Nutt et al., 2007).
With respect to the somewhat similar neurochemical effects inducedFig. 5. Effect of pridopidine on hyperlocomotoractivity induced by (A) D-amphetamine
and (B) MK-801. *Pb0.05, **Pb0.01, ***Pb0.001.by olanzapine and pridopidine, it is noteworthy that olanzapine is
used clinically, in combination with ﬂuoxetine, for the acute
treatment of depressive episodes associated with bipolar I disorder
and treatment-resistant major depressive disorder (Croxtall and
Scott, 2010).
4.3. Behavioural stabilizing effect of pridopidine and the putative role of
dopamine D2 receptor interactions
Environmental stimuli, such as a novel cage, induce an increase of
both cortical and subcortical extracellular dopamine (Feenstra et al.,
2000). In our normal state experiments, the rats were introduced to a
novel cage (the motility meter arenas) 4 min after pridopidine
administration. Hence, during the ﬁrst minutes of these normal
state experiments, locomotor activity and extracellular dopamine
would both be expected to be elevated compared with rats that are
habituated to their environment. In the habituated-state experiments,
pridopidine induced a moderate but deﬁnite stimulation of motor
activity, whereas stimulation of motor activity was not evident during
the ﬁrst 15 min of the normal state experiments. Furthermore, in
preclinical models of hyperlocomation, due to either hyper-dopami-
nergia or hypoglutamatergia, pridopidine displayed dose-dependent
reductions of locomotor activity. Hence, the effects of pridopidine
were state dependent (see also (Natesan et al., 2006; Pettersson et al.,
2010)).
The behaviour stabilizing effect of pridopidine is not explained solely
by the speciﬁc interaction with dopamine D2 receptors. In vitro data on
interactions of pridopidine at the receptor level, such as surmountable
and fast-off receptor kinetics, may account for the lack of reduction of
spontaneous locomotor activity over a wide dose range. The increase in
motor activity in habituated animalsmay also be regarded as aneffect of
the blockade of the dopamine D2High receptors on the presynaptic site,
leading to moderately increased levels of dopamine in the synapse,
subsequently stimulating postsynaptic dopamine D2 receptors and
inducing an increase in motor activity, provided that dopamine D2
receptor afﬁnity is not too high (see (Pettersson et al., 2010)). However,
because data support activation of dopamine, noradrenaline and
glutamate systems in the cortex by pridopidine, interactions with
these systems may underlie the differences in vivo versus typical,
neuroleptic-like dopamineD2 receptor antagonists. Pridopidine, but not
thedopamineD2 receptor antagonist haloperidol, signiﬁcantly inhibited
amphetamine-inducedhyperactivity in dopamineD2 receptor knockout
mice (Svensson et al., 2009). Hence, the reductions of locomotor activity
in the hyperactive states could be explained, in part, by the cortical
activation proﬁle displayed by pridopidine. An increase in cortical
noradrenaline (e.g. by alpha2 adrenoceptor blockade) has been
suggested to augment prefrontal dopamine functioning (Svensson,
94 H. Ponten et al. / European Journal of Pharmacology 644 (2010) 88–952003) and adjunctive treatment with the alpha2 adrenoceptor antag-
onist idazoxan improves antipsychotic efﬁcacy in preclinical models
(Hertel et al., 1999; Marcus et al., 2009) compared with dopamine D2
receptor antagonists alone. In vitro, the combination of idazoxan with
the dopamine D2 receptor antagonist raclopride has been shown to
cause a dopamine D1 receptor-mediated facilitation of glutamate
transmission in rat prefrontal pyramidal cells (Marcus et al., 2005).
Increased expression of Arc mRNA in rat cortex after administra-
tion of pridopidine, interpreted as increased synaptic glutamate
activation of ionotropic NMDA receptors (Waters et al., 2009a),
could possibly be dependent primarily on the cortical increase in
dopamine and noradrenaline. Increased cortical activation would
strengthen cortical–striatal feedback regulation of psychomotor
activity (Alexander et al., 1986), leading to behavioural normalization
of hyperactive states (Tekin and Cummings, 2002). Glutamate
inﬂuence on psychomotor functions in rodents is supported by data
showing that LY404039, a glutamate receptor mGlu2/3 agonist,
inhibits D-amphetamine-induced hyperactivity without sedative
effects (Rorick-Kehn et al., 2007) — a similar effect to that seen with
pridopidine.
Taken together, these results suggest that the psychomotor
stabilizing effects of pridopidine may be dependent on its dual
effects: the functional antagonism of subcortical dopamine transmis-
sion and strengthening of cortical glutamate transmission. The
properties of dopaminergic stabilizers should therefore be regarded
as an in vivo phenomenon, dependent on the effects in the cortico–
subcortical brain circuitries not revealed at the receptor level in vitro.4.4. Clinical implications of the pharmacological proﬁle
The preclinical proﬁle of pridopidine includes the potential to
stabilize motor function not only in hyperactivity, but also in states of
hypoactivity. Furthermore, pridopidine displays antidepressant po-
tential, as indicated by the tail suspension test data. It has been
suggested that facilitation of prefrontal cortical dopamine levels,
leading to stimulation of dopamine D1 receptors, could attenuate
some cognitive impairments associated with deﬁcits in NMDA
receptor function (Krystal et al., 2005). Hence the increased
extracellular concentrations of dopamine in the prefrontal cortex
induced by pridopidine, in combination with the putative enhanced
activation by pridopidine of synaptic NMDA receptors in the cortex,
imply it could be beneﬁcial for restoring impaired cortical activity.
Indeed, pridopidine has shown beneﬁcial effects in NMDA receptor
antagonist rat models of cognitive and negative symptoms of
schizophrenia (Nilsson et al., 2004; Rung et al., 2005). Huntington's
disease leads to damage of neurons in both the striatum and the
cortex, causing regional hypo- and hyperactivity in the dopamine
systems. Symptoms of HD include severe motor disturbances (lack of
voluntarymovements as well as presence of involuntarymovements),
cognitive impairment and psychiatric characteristics, including
psychosis and depression. Thus, the in vivo pharmacological-effect
proﬁle of pridopidine suggests it may have signiﬁcant beneﬁts on the
main symptom domains in HD. In an early study in HD, pridopidine
was associated with improvements in voluntary motor performance,
with no change in involuntary movement (Tedroff et al., 2009).Acknowledgements
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